Martingale Asset Management’s Vaxcyte PCVX Stock Holding History

Martingale Asset Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.18M	Buy	37,545 +13,553	+56%	+$736K	0.05%	371
2026 Q1	$1.39M	Hold	23,992	–	–	0.04%	421
2025 Q4	$1.11M	Buy	23,992 +401	+2%	+$17.9K	0.03%	453
2025 Q3	$850K	Buy	23,591 +11,452	+94%	+$379K	0.02%	519
2025 Q2	$395K	Buy	+12,139	New	+$398K	0.01%	657
2024 Q4	–	Sell	-15,605	Closed	-$1.78M	–	832
2024 Q3	$1.78M	Sell	15,605 -1,664	-10%	-$150K	0.04%	342
2024 Q2	$1.3M	Buy	17,269 +1,429	+9%	+$97.3K	0.03%	393
2024 Q1	$1.08M	Sell	15,840 -3	-0%	-$208	0.02%	452
2023 Q4	$995K	Buy	+15,843	New	+$823K	0.02%	449
2022 Q4	–	Sell	-33,513	Closed	-$806K	–	870
2022 Q3	$806K	Buy	+33,513	New	+$850K	0.02%	497

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Martingale Asset Management's PCVX Position: Q2 2026 in Review

Martingale Asset Management increased its Vaxcyte (PCVX) stake by 56% in Q2 2026, buying an estimated $736K and bringing the position to 37,545 shares worth $2.18M. The position accounts for 0.05% of the portfolio, ranked #371.

Martingale Asset Management first reported a position in PCVX in Q3 2022 and has held it in 10 quarters since. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Martingale Asset Management held 37,545 shares of Vaxcyte worth $2.18M as of Q2 2026.
Martingale Asset Management bought 13,553 Vaxcyte shares in Q2 2026, an estimated $736K.
Vaxcyte made up 0.05% of Martingale Asset Management's portfolio in Q2 2026, its #371 holding.
Martingale Asset Management first reported a position in Vaxcyte in Q3 2022 and has held it in 10 quarters since.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Martingale Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.